Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyaluronidase for Post-Stroke Upper Limb Muscle Stiffness
NCT03306615Phase 2Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Oct 2021
- Primary completion
- Jun 2026
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant human hyaluronidase PH20 in Spasticity (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Most affected upper limb joint passive range of motion at 15 weeks. Started Oct 2021; status: active, not recruiting.
02
Drugs
recombinant human hyaluronidase PH20
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT03306615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306615.